Analysts are calling for 25% top-line growth from Intuitive Surgical this year, to be followed by 15% and 17% revenue growth ...

The stock's fall snapped a three-day winning streak.

Journavx is the first truly new painkiller approved by the Food and Drug Administration in more than 20 years. But the drug ...

This was the stock's second consecutive day of gains.

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its second quarter 2025 financial results on Monday, August 4, ...

Investing at least part of the initial $1,000 in an artificial intelligence (AI) stock is a smart move. Despite impressive ...

Whales with a lot of money to spend have taken a noticeably bearish stance on Vertex Pharmaceuticals. If we consider the specifics of each trade, it is accurate to state that 9% of the investors ...

PGIM Jennison Health Sciences Fund released its first quarter 2025 investor letter. A copy of the letter can be downloaded ...

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

Vertex Pharmaceuticals Incorporated remains a top Buy with a strong cystic fibrosis franchise, innovative pipeline, and cell therapies. Click for my VRTX update.

Vertex Pharmaceuticals’ cystic fibrosis (CF) therapy Alyftrek (deutivacaftor/tezacaftor/vanzacaftor) has been approved by the European Commission (EC).

In another article, we covered Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) and shared the list of best fundamental stocks to buy according to hedge funds.